Myocardial Ischemia - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 77 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Myocardial Ischemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Myocardial Ischemia - Pipeline Review, H2 2014', provides an overview of the Myocardial Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Myocardial Ischemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myocardial Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Myocardial Ischemia Overview 8
Therapeutics Development 9
Pipeline Products for Myocardial Ischemia - Overview 9
Pipeline Products for Myocardial Ischemia - Comparative Analysis 10
Myocardial Ischemia - Therapeutics under Development by Companies 11
Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes 12
Myocardial Ischemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Myocardial Ischemia - Products under Development by Companies 16
Myocardial Ischemia - Products under Investigation by Universities/Institutes 17
Myocardial Ischemia - Companies Involved in Therapeutics Development 18
Baxter International Inc. 18
CoDa Therapeutics, Inc. 19
Lixte Biotechnology Holdings, Inc. 20
Miltenyi Biotec GmbH 21
Nyken BV 22
Opsona Therapeutics Ltd. 23
ViroMed Co., Ltd. 24
Myocardial Ischemia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
alferminogene tadenovec - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AntimiR-199a - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
EP-80317 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gene Therapy for Ischemic Heart Failure - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LB-100 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LB-102 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NYK-1112 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
OPN-305 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Peptagon - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PMC-6 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Stem Cell Therapy for Cardiovascular Disease - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VM-202 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Myocardial Ischemia - Recent Pipeline Updates 59
Myocardial Ischemia - Dormant Projects 65
Myocardial Ischemia - Product Development Milestones 66
Featured News & Press Releases 66
Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 66
Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 66
Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 67
Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 67
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 68
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 70
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 72
May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched 72
Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 73
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products under Development for Myocardial Ischemia, H2 2014 9
Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Myocardial Ischemia - Pipeline by Baxter International Inc., H2 2014 18
Myocardial Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2014 19
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 20
Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2014 21
Myocardial Ischemia - Pipeline by Nyken BV, H2 2014 22
Myocardial Ischemia - Pipeline by Opsona Therapeutics Ltd., H2 2014 23
Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Myocardial Ischemia Therapeutics - Recent Pipeline Updates, H2 2014 59
Myocardial Ischemia - Dormant Projects, H2 2014 65